Renal Cell Carcinoma Incidence, Costs, and Survival in Taiwan, 1998-2016

A population-based cohort study by Chin-Heng Lu analyzes 14,131 renal cell carcinoma cases diagnosed in Taiwan between 1998 and 2016. It uses data from the Taiwan National Health Insurance Research Database and Cancer Registry to evaluate life expectancy, loss of life expectancy, and lifetime medical costs. The study specifically compares outcomes and costs for patients receiving targeted therapy versus non-targeted therapy.

Use Cases

• Modeling the cost-effectiveness of targeted therapies based on real-world survival and cost data.
• Analyzing trends in renal cell carcinoma incidence rates over time, segmented by gender.
• Estimating loss of life expectancy for cancer patients based on age and treatment type.
• Evaluating the relationship between lifetime medical costs and survival outcomes in a specific healthcare system.

Strengths

• Based on a large cohort of 14,131 patient cases from national databases.
• Provides specific incidence rates (e.g., 0.37% to 0.73% in men) and life expectancy figures (e.g., 4.43 years for targeted therapy).
• Covers a long time range from 1998 to 2016, allowing for trend analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the Taiwan healthcare system.

Provenance

Source

Taiwan National Health Insurance Research Database and Cancer Registry.

Collection Method

Population-based cohort study.

Time Range

1998 to 2016

Freshness

Last updated 2026-04-15 05:44:07; freshness should be verified.

Geography

Taiwan